Piperlongumine was suggested to increase the activity of recombinant ALDH2 and protect it from inactivation by lipid aldehydes [75]; thus, we speculated that this drug could play a role in the treatment of prostate cancer in the future. This evidence concerns the gene ALDH2 and prostate carcinoma.